CD40LG and systemic lupus erythematosus: Patients involved in phase I/II trials who received anti-CD40L-blocking therapy for proliferative lupus glomerulonephritis, multiple myeloma, non-Hodgkin’s lymphoma, and systemic lupus erythematosus showed clinical improvement [41–45].